Antimicrobial resistance (AMR) is a global threat for the effective prevention and treatment of infectious diseases caused by multi-drug resistant (MDR) Gram-negative bacteria. Most dangerous of this pathogens are Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae. Infectious disease society of America (IDSA) has placed these three problematic pathogens on a hit list of the six top-priority dangerous MDR microorganisms. In 2013 the Centers for Disease Control and Prevention (CDC) escalated the antibiotic resistance threat level for these bacteria in the USA as being serious to urgent. Clinicians worldwide, including Australia (Australian Society for Infectious Diseases Gram-negative superbugs meeting, 2013), are increasingly confronted with the reality of infections with Gram-negative pathogens that are resistant to all antibiotics except polymyxins.
Polymyxins are used as the last-line therapy against Gram-negative superbugs. Current dosing recommendations of parenteral polymyxins are suboptimal, in particular for lung infections due to very limited access of polymyxins into the infection site. Moreover, nephrotoxicity is the dose-limiting factor and can occur in up to 60% of patients. Pulmonary delivery of polymyxins thus holds a great promise for treatment of lung infections with minimum systemic exposure. Unfortunately, there is a lack of information on the pharmacokinetics (PK) and pharmacodynamics (PD) for inhaled polymyxins. Worryingly, emergence of polymyxin resistance due to suboptimal use has been increasingly reported worldwide.
My research interest is to elucidate the toxicity and mechanism of disposition of polymyxins in lung epithelial cells using cutting-edge imaging techniques, metabolomics and experimental animal model. I am also interested in attenuation of polymyxin induced lung toxicity by co-administration of potential protective agents.

Primary Affiliation: University of Dhaka - Dhaka, Dhaka , Bangladesh

Specialties: Pharmacology, Pharmacogenomics, Pharmacogenetics

Research Interests: Antimicrobial Pharmacology and Toxicology

  • 2015
    Doctor of Philosophy (3rd year) Monash University
  • 2007
    Master of Pharmacy University of Dhaka
  • 2006
    Bachelor of Pharmacy University of Dhaka


Association of BRCA1, BRCA2, RAD51, and HER2 gene polymorphisms with the breast cancer risk in the Bangladeshi population.
Breast Cancer 2017 Mar 11;24(2):229-237. Epub 2016 Apr 11.
Department of Clinical Pharmacy and Pharmacology, Faculty of Pharmacy, University of Dhaka, Dhaka, 1000, Bangladesh.

Breast cancer risk in relation to TP53 codon 72 and CDH1 gene polymorphisms in the Bangladeshi women.
Tumour Biol 2016 Jun 14;37(6):7229-37. Epub 2015 Dec 14.
Department of Clinical Pharmacy and Pharmacology, Faculty of Pharmacy, University of Dhaka, Dhaka, 1000, Bangladesh.